{"prompt": "['MK-7902', 'PAGE 12', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'At least 1 laboratory, vital sign, or ECG measurement obtained subsequent to at least 1 dose of', 'study intervention is required for inclusion in the analysis of the respective safety parameter. To', 'assess change from baseline, a baseline measurement is also required.', '3.5.3.', 'Patient-reported Outcome Analysis Population', 'The PRO analyses are based on the PRO Full Analysis Set (PRO FAS) population, defined as all', 'randomized participants who have at least one PRO assessment available and have received at', 'least one dose of the study intervention. Participants will be analyzed in the treatment group to', 'which they were randomized.', '3.5.4.', 'Pharmacokinetic Analysis Population', 'The population of PK analysis set includes all the participants who have received at least 1 dose', 'of study intervention with documented dosing history in the lenvatinib + pembrolizumab arm', 'and have measurable plasma levels of lenvatinib or serum levels of pembrolizumab.', '3.6. Statistical Methods', '3.6.1.', 'Statistical Methods for Efficacy Analyses', 'This section describes the statistical methods that address the primary and secondary efficacy', 'objectives. Efficacy results that will be deemed to be statistically significant after consideration', 'of the Type I error control strategy are described in Section 3.8. Nominal p values will be', 'computed for other efficacy analyses, but should be interpreted with caution because of potential', 'issues of multiplicity.', 'The stratification factors used for randomization (see Section 6.3.2 in the protocol) will be', 'applied to all stratified analyses, in particular, the stratified log-rank test, stratified Cox model,', 'and stratified Miettinen and Nurminen method [Miettinen, O. 1985].', 'The efficacy analyses for OR, DOR and PFS will include responses and documented progression', 'events that occur prior to second course treatment.', 'A summary of the primary analysis strategy for the key efficacy endpoints is provided in Table', '1.', 'C', 'Confidential']['MK-7902', 'PAGE 13', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 1 Analysis Methods for Key Efficacy Endpoints', 'Endpoint/Variable', 'Statistical Method', 'Analysis', 'Population', 'Missing Data Approach', 'Primary Analyses:', 'PFS (RECIST 1.1)', 'Testing: stratified log-rank test', 'ITT', 'Censored according to rules in', 'by BICR', 'Estimation: Stratified Cox model', 'Table 2', \"with Efron's tie-handling method\", 'OS', 'Testing: stratified log-rank test', 'ITT', 'Censored at last known alive date', 'Estimation: Stratified Cox model', \"with Efron's tie-handling method\", 'Secondary Analyses:', 'ORR (RECIST 1.1)', 'Testing and estimation:', 'ITT', 'Participants with missing data are', 'by BICR', 'stratified Miettinen and Nurminen', 'considered nonresponders', 'method', 'Abbreviations: BICR = blinded independent central review; ITT = intention-to-treat ORR = objective response', 'rate; os = overall survival; PFS = progression-free survival; RECIST 1.1 = Response Evaluation Criteria in Solid', 'Tumors.', 'The strategy to address multiplicity issues with regard to multiple endpoints and interim analyses', 'is described in Section 3.7, Interim Analyses, and in Section 3.8, Multiplicity.', '3.6.1.1.', 'Progression-free Survival', 'The nonparametric Kaplan-Meier method will be used to estimate the PFS curve in each', 'treatment group. The hypotheses of treatment difference in PFS will be tested by the stratified', \"log-rank test. A stratified Cox proportional hazard model with Efron's method of tie handling\", 'will be used to estimate the magnitude of the treatment difference (ie, HR) between the treatment', \"arms. The HR and its 95% CI from the stratified Cox model with Efron's method of tie handling\", 'and with a single treatment covariate will be reported. The stratification factors used for', 'randomization (Section 6.3.2 in the protocol) will be applied to both the stratified log-rank test', 'and the stratified Cox model.', 'Since PD is assessed periodically, PD can occur any time in the time interval between the last', 'assessment where PD was not documented and the assessment when PD is documented. For the', 'primary analysis, for the participants who have PD, the true date of PD will be approximated by', 'the date of the first assessment at which PD is objectively documented per RECIST 1.1 by the', 'BICR vendor, regardless of discontinuation of study drug.', 'To evaluate the robustness of the PFS endpoint per RECIST 1.1 via BICR by the imaging', 'vendor, 1 primary and 2 sensitivity analyses with a different set of censoring rules will be', 'performed. For the primary analysis, if the events (PD or death) are immediately after more than', '1 consecutive missed disease assessment, the data are censored at the last disease assessment', 'before missing visits. Also data after new anticancer therapy are censored at the last disease', 'assessment before the initiation of new anticancer therapy. The first sensitivity analysis follows', 'ITT principles (ie, PDs/deaths are counted as events regardless of missed study visits or initiation', 'Confidential']\n\n###\n\n", "completion": "END"}